681 related articles for article (PubMed ID: 32711187)
1. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.
Somm E; Montandon SA; Loizides-Mangold U; Gaïa N; Lazarevic V; De Vito C; Perroud E; Bochaton-Piallat ML; Dibner C; Schrenzel J; Jornayvaz FR
Transl Res; 2021 Jan; 227():75-88. PubMed ID: 32711187
[TBL] [Abstract][Full Text] [Related]
2. Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor.
Aljobaily N; Krutsinger K; Viereckl MJ; Joly R; Menlove B; Cone B; Suppes A; Han Y
Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615835
[TBL] [Abstract][Full Text] [Related]
3. Alanyl-Glutamine Protects Mice against Methionine- and Choline-Deficient-Diet-Induced Steatohepatitis and Fibrosis by Modulating Oxidative Stress and Inflammation.
Hu J; Zheng Y; Ying H; Ma H; Li L; Zhao Y
Nutrients; 2022 Sep; 14(18):. PubMed ID: 36145172
[TBL] [Abstract][Full Text] [Related]
4. Soyasaponin A
Xiong F; Zheng Z; Xiao L; Su C; Chen J; Gu X; Tang J; Zhao Y; Luo H; Zha L
Mol Nutr Food Res; 2021 Jul; 65(14):e2100067. PubMed ID: 34047448
[TBL] [Abstract][Full Text] [Related]
5. Mosapride citrate improves nonalcoholic steatohepatitis with increased fecal lactic acid bacteria and plasma glucagon-like peptide-1 level in a rodent model.
Okubo H; Nakatsu Y; Sakoda H; Kushiyama A; Fujishiro M; Fukushima T; Matsunaga Y; Ohno H; Yoneda M; Kamata H; Shinjo T; Iwashita M; Nishimura F; Asano T
Am J Physiol Gastrointest Liver Physiol; 2015 Jan; 308(2):G151-8. PubMed ID: 25428903
[TBL] [Abstract][Full Text] [Related]
6. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
[TBL] [Abstract][Full Text] [Related]
7. Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis.
Chiu HY; Tsai SC; Tsai FJ; Lo YH; Cheng CC; Liu TY; Jhan SR; Yang JS; Chiu YJ
In Vivo; 2023; 37(3):1037-1046. PubMed ID: 37103096
[TBL] [Abstract][Full Text] [Related]
8. Impact of global PTP1B deficiency on the gut barrier permeability during NASH in mice.
Rubio C; Puerto M; García-Rodríquez JJ; Lu VB; García-Martínez I; Alén R; Sanmartín-Salinas P; Toledo-Lobo MV; Saiz J; Ruperez J; Barbas C; Menchén L; Gribble FM; Reimann F; Guijarro LG; Carrascosa JM; Valverde ÁM
Mol Metab; 2020 May; 35():100954. PubMed ID: 32244182
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
10. Theabrownin ameliorates liver inflammation, oxidative stress, and fibrosis in MCD diet-fed C57BL/6J mice.
Zhen Q; Liang Q; Wang H; Zheng Y; Lu Z; Bian C; Zhao X; Guo X
Front Endocrinol (Lausanne); 2023; 14():1118925. PubMed ID: 36742397
[TBL] [Abstract][Full Text] [Related]
11. Glucagon Like Peptide-1 Receptor Agonists Alter Pancreatic and Hepatic Histology and Regulation of Endoplasmic Reticulum Stress in High-fat Diet Mouse Model.
Fang T; Huang S; Chen Y; Chen Z; Chen J; Hu W
Exp Clin Endocrinol Diabetes; 2021 Sep; 129(9):625-633. PubMed ID: 32961563
[TBL] [Abstract][Full Text] [Related]
12. Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet.
Ding Y; Sun X; Chen Y; Deng Y; Qian K
Eur J Pharmacol; 2015 Aug; 761():405-12. PubMed ID: 25967348
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis.
Kojima M; Takahashi H; Kuwashiro T; Tanaka K; Mori H; Ozaki I; Kitajima Y; Matsuda Y; Ashida K; Eguchi Y; Anzai K
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32785012
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
[TBL] [Abstract][Full Text] [Related]
16. Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis.
Ye JZ; Li YT; Wu WR; Shi D; Fang DQ; Yang LY; Bian XY; Wu JJ; Wang Q; Jiang XW; Peng CG; Ye WC; Xia PC; Li LJ
World J Gastroenterol; 2018 Jun; 24(23):2468-2481. PubMed ID: 29930468
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice.
Yamamoto T; Nakade Y; Yamauchi T; Kobayashi Y; Ishii N; Ohashi T; Ito K; Sato K; Fukuzawa Y; Yoneda M
World J Gastroenterol; 2016 Feb; 22(8):2512-23. PubMed ID: 26937139
[TBL] [Abstract][Full Text] [Related]
18. Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis.
Jung YA; Choi YK; Jung GS; Seo HY; Kim HS; Jang BK; Kim JG; Lee IK; Kim MK; Park KG
Diabetes Res Clin Pract; 2014 Jul; 105(1):47-57. PubMed ID: 24842243
[TBL] [Abstract][Full Text] [Related]
19. Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy.
Valdecantos MP; Ruiz L; Pardo V; Castro-Sanchez L; García-Monzón C; Lanzón B; Rupérez J; Barbas C; Naylor J; Trevaskis JL; Grimsby J; Rondinone CM; Valverde ÁM
Sci Rep; 2018 Nov; 8(1):16461. PubMed ID: 30405191
[TBL] [Abstract][Full Text] [Related]
20. The transition from fatty liver to NASH associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet.
Wortham M; He L; Gyamfi M; Copple BL; Wan YJ
Dig Dis Sci; 2008 Oct; 53(10):2761-74. PubMed ID: 18299981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
